Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 11/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583833 | 1.00 | LSS (0.65) | LSS | |
| SCHEMBL188732 | 0.89 | LSS (0.78) | LSS | |
| SCHEMBL1009221 | 0.89 | LSS (0.78) | LSS | |
| SCHEMBL1142772 | 0.89 | LSS (0.78) | LSS | |
| SCHEMBL1401906 | 0.89 | LSS (0.78) | LSS | |
| SCHEMBL29711785 | 0.84 | LSS (0.83) | LSS | |
| SCHEMBL29711771 | 0.84 | LSS (0.83) | LSS | |
| SCHEMBL2833064 | 0.81 | LSS (0.66) | LSS | |
| SCHEMBL19105136 | 0.79 | LSS (0.46) | LSS | |
| SCHEMBL4053634 | 0.78 | KMT2A (0.49) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111108213-B | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2024-12-13 | — | — | CN | claimed |
| CN-111108213-A | Process for preparing high intensity sweeteners | 弗门尼舍公司 | 2020-05-05 | — | — | CN | claimed |
| CN-119709929-A | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-113302298-B | Biosynthesis of mogrosides | 银杏生物制品公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-111108213-B | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-117460825-A | Biosynthesis of isoprenoids and their precursors | 银杏生物制品公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20220378072-A1 | BIOSYNTHESIS OF MOGROSIDES | GINKGO BIOWORKS, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| CN-115335514-A | Biosynthesis of mogrosides | 银杏生物制品公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4048782-A1 | BIOSYNTHESIS OF MOGROSIDES | Ginkgo Bioworks, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-113316394-A | Process for preparing high intensity sweeteners | 弗门尼舍公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-113286523-A | Process for preparing high intensity sweeteners | 弗门尼舍公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-0808374-A1 | METHOD FOR MODULATING PROCESSES MEDIATED BY FARNESOID ACTIVATED RECEPTORS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-11-26 | — | — | EP | disclosed |
| CN-1160403-A | Substd. heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
| WO-1996021742-A1 | METHOD FOR MODULATING PROCESSES MEDIATED BY FARNESOID ACTIVATED RECEPTORS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0676960-A4 | — | — | 1995-11-15 | — | — | EP | disclosed |
| EP-0676960-A1 | CYCLOALKYL AMINE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5384252-A | Cyclization of an unsaturated molecule with sulfonate leaving group | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1995000146-A1 | AMINO BI- AND TRI-CARBOCYCLIC ALKANE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994027601-A1 | ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994014435-A1 | CYCLOALKYL AMINE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378072-A1 | BIOSYNTHESIS OF MOGROSIDES | SQLE, POR, OXER1 | LSS 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.